• Molecular NameOxaprozin
  • SynonymOxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]
  • Weight293.322
  • Drugbank_IDDB00991
  • ACS_NO21256-18-8
  • Show 2D model
  • LogP (experiment)4.19
  • LogP (predicted, AB/LogP v2.0)3.92
  • pka4.3
  • LogD (pH=7, predicted)1.5
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.55
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds5
  • TPSA63.33
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
  • Absorption_value98.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability98.0
  • Protein binding99.0
  • Volume of distribution (VD)0.14~0.24 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.?5% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites.
  • Half life54.9 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=4470 mg/kg
  • LD50 (mouse)LD50=1210 mg/kg